A phase Ib/II trial (NCT03643549, https://clinicaltrials.gov/study/NCT03643549, accessed on 27 October 2024) is investigating the safety and survival benefits for patients with recurrent grade-4 gliomas with unmethylated MGMT promoter treated with bortezomib and temozolomide [186]. The gene discussed is MGMT; the disease is central nervous system cancer.